Present at a conference, Ioan Nani, the general director of Antibiotice Iasi, pointed out that the Romanian pharmaceutical industry’s production currently stands at EUR 600-650 M, and the real production capacity of the top 4 or 5 Romanian producers is at least 40 per cent higher. “I consider that the current platforms in Romania can raise the production to around EUR 1 bln, but we have to take into account a very important aspect: a Romanian product will on average be sold for RON 1.75, compared to a product sold on the Romanian market in general at RON 3.5 per unit. The Romanian production can reach 50 per cent of consumption but we have to see how it is divided into therapeutic classes,” Nani added. Terapia Ranbaxy, Zentiva (formerly Sicomed), Antibiotice Iasi, Labormed Alvogen and Biofarm are some of the main producers of pharmaceutical drugs in Romania. Europharm Brasov was also an important plant on the local market but the unit will be shut down next year following a decision taken by Britain’s GSK Group, the plant’s owner.